ClinicalTrials.gov
public full text
Public Domain
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Importance of Achieving High Treatment Targets in Atopic Dermatitis: A Narrative Review#299100
- A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis#910387
- Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis#847710
- Achieving minimal disease activity in atopic dermatitis is associated with fewer flares, reduced healthcare resource utilization, and improved disease control: analysis from the real-world MEASURE-AD study#1015167
- Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.#1165138
Record · ID 845579
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive